Last reviewed · How we verify
Prestige Biopharma Limited — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| HD201 | HD201 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| HD204 | HD204 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ADvantage Therapeutics · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
- 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Prestige Biopharma Limited:
- Prestige Biopharma Limited pipeline updates — RSS
- Prestige Biopharma Limited pipeline updates — Atom
- Prestige Biopharma Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Prestige Biopharma Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/prestige-biopharma-limited. Accessed 2026-05-16.